Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its ...

Bristol-Myers Squibb (BMY) shares rise after beating Q2 forecasts, raising 2025 revenue outlook, and showcasing growth in key ...

Bristol-Myers Squibb Company ( NYSE: BMY) is scheduled to announce Q2 earnings results on July 31st, before markets open.

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...